The NM_000152.5:c.1645G>A variant in GAA is a missense variant predicted to cause substitution of glycine by arginine at amino acid 549 (p.Gly549Arg). This variant is absent in gnomAD v4.1.1 (PM2_Supporting). This variant has been reported in two probands diagnosed with Pompe disease. The first proband, diagnosed with juvenile-onset Pompe disease, was reported to have deficient GAA activity but values were not provided. This individual was reported to be compound heterozygous for this variant and an unidentified variant (PMID: 14695532). The second proband, diagnosed with infantile-onset Pompe disease, was also reported to have deficient GAA activity levels but values were not provided. This individual was reported to be compound heterozygous for this variant and an unidentified variant (PMID: 40225932) (PP4, PM3_Not Met). Expression of the variant in COS cells resulted in 13.0% wild-type GAA activity, 3.0% wild-type GAA activity in medium, and 18.6% glycogen compared to wild-type cells. Additionally, an aberrant pattern of processing was observed via Western blot, indicating the variant may impact protein synthesis (PMID: 14695532) (PS3_Supporting). The computational predictor REVEL gives a score of 0.878 which is above the threshold predicting a damaging impact on GAA function (>0.7) (PP3). The same amino acid change (p.Gly549Arg), resulting from a different nucleotide change (c.1645G>C; ClinVar Variation ID 3769497), is classified as likely pathogenic for Pompe disease by the ClinGen Lysosomal Diseases VCEP (Accession: SCV006333385.1) (PS1_Moderate). There is a ClinVar entry for this variant (Variation ID: 2202283). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0.0): PM2_Supporting, PP3, PS1_Moderate, PS3_Supporting, PP4. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel, June 2, 2026).